Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Theramex were searching for a platform to digitise the manual processes across their R&D landscape
The only robotic-arm assisted surgical device to conduct joint replacement with accuracy and better clinical outcomes
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs
Subscribe To Our Newsletter & Stay Updated